Pappa Maria, Kosmetatou Maria, Elezoglou Antonia, Boki Kyriaki, Konstantopoulou Pinelopi, Papagoras Charalampos, Garyfallos Alexandros, Vassilopoulos Dimitrios, Sidiropoulos Prodromos, Sfikakis Petros, Boumpas Dimitrios, Bertsias George, Tektonidou Maria, Fanouriakis Antonis
First Department of Propaedeutic Internal Medicine, National and Kapodistrian University of Athens, "Laiko" General Hospital, Athens.
Rheumatology Unit, Fourth Department of Propaedeutic Internal Medicine, National and Kapodistrian University of Athens, "Attikon" University Hospital, Athens.
Mediterr J Rheumatol. 2022 Jun 30;33(2):263-267. doi: 10.31138/mjr.33.2.263. eCollection 2022 Jun.
Lupus nephritis (LN) affects a significant proportion of patients with systemic lupus erythematosus (SLE) and is characterised by increased morbidity and mortality. The updated joint EULAR/European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) recommendations for the management of LN have set as target of therapy the optimisation (preservation or improvement) of kidney function, accompanied by a reduction in proteinuria of at least 25% by 3 months, 50% by 6 months, and below 500-700 mg/g by 12 months (complete clinical response). It is currently unknown what proportion of Greek patients with LN reach these proposed targets with the current available treatments. At the same time, recent successful phase 3 trials have led to the approval of both belimumab and voclosporin for the treatment of patients with LN and have steered discussions as to whether the "induction-maintenance" paradigm should be substituted by an early combination treatment for all patients. To inform future therapeutic decisions and facilitate the positioning of these new drugs in the therapeutic algorithm of LN, the current study protocol aims to map the unmet needs in the treatment of LN in Greece, by quantifying the proportion of patients who attain the recommended treatment targets in everyday clinical practice.
狼疮性肾炎（LN）影响着很大一部分系统性红斑狼疮（SLE）患者，其特征是发病率和死亡率增加。欧洲抗风湿病联盟/欧洲肾脏协会 - 欧洲透析与移植协会（ERA - EDTA）联合发布的关于LN管理的最新建议将治疗目标设定为优化（保留或改善）肾功能，同时在3个月内使蛋白尿减少至少25%，6个月内减少50%，12个月内降至500 - 700mg/g以下（完全临床缓解）。目前尚不清楚希腊LN患者通过现有治疗达到这些建议目标的比例是多少。与此同时，近期成功的3期试验已使贝利尤单抗和voclosporin获批用于治疗LN患者，并引发了关于是否应将“诱导 - 维持”模式替换为对所有患者采用早期联合治疗的讨论。为了为未来的治疗决策提供信息，并促进这些新药在LN治疗方案中的定位，本研究方案旨在通过量化在日常临床实践中达到推荐治疗目标的患者比例，来明确希腊LN治疗中未满足的需求。
